What Is Zepbound? A Plain-Language Explainer

Zepbound is one of the newer names in a crowded field of weight-loss injectables, and it’s easy to lose track of which drug is which. Here’s the plain-language version: Zepbound is tirzepatide, made by Eli Lilly, and it works differently from the semaglutide drugs (Ozempic, Wegovy) that came before it.

Vegetables landscape, nature, garden — illustrating What Is Zepbound? A Plain-Language Explainer

What is tirzepatide, exactly?

Tirzepatide is what’s called a dual agonist — it activates two hormone receptors instead of one. Older GLP-1 drugs like semaglutide mimic a single gut hormone, GLP-1, that slows digestion and reduces appetite. Tirzepatide does that too, but it also activates the GIP receptor, a second hormone pathway involved in insulin response and fat metabolism. The theory, and the trial data so far, suggest hitting both pathways produces larger average weight loss than GLP-1 alone, though head-to-head comparisons across different trials always come with caveats about differing populations and designs.

Zepbound is injected once a week using a prefilled pen, starting at a low dose and increasing gradually — a pattern called dose titration that’s standard across this drug class and meant to reduce nausea and other GI side effects as the body adjusts.

What did the trials actually show?

The pivotal trial for weight loss was SURMOUNT-1, published in the New England Journal of Medicine. It enrolled adults with obesity, or overweight with at least one weight-related condition, who did not have type 2 diabetes. Participants were randomized to different tirzepatide doses or placebo, all combined with lifestyle counseling on diet and exercise, and followed for about 72 weeks.

At the highest tested dose (15 mg weekly), participants lost roughly 21% of their body weight on average — noticeably more than the placebo group, which lost a small amount attributable to the diet and exercise counseling alone. Lower doses produced smaller but still substantial average losses. As with every obesity drug trial, individual results varied widely: some people lost much more, some much less, and a portion of participants didn’t respond meaningfully at all.

Zepbound’s trial results are genuinely strong by the standards of pharmacological weight loss, but “average 21% loss” describes a group, not a guarantee for any one person — and the studies were done alongside counseling and support that real-world use may not fully replicate.

Croquettes, meal, yummy — illustrating What Is Zepbound? A Plain-Language Explainer

Zepbound and sleep apnea — a separate approval

In late 2024, the FDA expanded tirzepatide’s approved uses to include moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, based on the SURMOUNT-OSA trial. That study found that weight loss on tirzepatide was associated with meaningful reductions in a standard measure of apnea severity (the apnea-hypopnea index) compared with placebo. This matters because obesity is a major driver of OSA severity, and losing a significant amount of weight can reduce airway obstruction during sleep. It’s a good illustration of how a drug’s approved “indications” expand as new trials come in — Zepbound isn’t just a weight-loss drug on paper anymore.

New year’s eve, salmon, fish — illustrating What Is Zepbound? A Plain-Language Explainer

How is Zepbound different from Mounjaro?

This is the part that trips people up: Zepbound and Mounjaro are the same drug, tirzepatide, from the same manufacturer. Mounjaro was approved first, for improving blood sugar control in adults with type 2 diabetes. Zepbound is the identical molecule marketed and labeled specifically for chronic weight management (and now OSA) in people who meet weight-related eligibility criteria, whether or not they have diabetes.

	Zepbound	Mounjaro
Molecule	Tirzepatide	Tirzepatide
Manufacturer	Eli Lilly	Eli Lilly
FDA-approved use	Chronic weight management; moderate-to-severe OSA with obesity	Type 2 diabetes glycemic control
Dosing	2.5 mg up to 15 mg weekly (titrated)	2.5 mg up to 15 mg weekly (titrated)
Insurance pathway	Often requires weight-related diagnosis codes	Often requires diabetes diagnosis

Because the molecule is identical, the side-effect profile is too. The most common issues in trials were gastrointestinal — nausea, diarrhea, constipation, and vomiting — most pronounced during dose increases and typically easing over time, though not for everyone. Less common but more serious risks flagged in labeling include gallbladder problems and pancreatitis; people with a personal or family history of certain thyroid cancers are advised against these drugs based on findings in rodent studies, a signal that hasn’t been established in humans but is treated cautiously.

The takeaway

Zepbound is tirzepatide, a dual-hormone injectable that produced some of the largest average weight-loss numbers seen in an obesity drug trial to date, and it now has a second FDA approval for sleep apnea tied to that weight effect. It is not a fundamentally different drug from Mounjaro — it’s the same molecule with a different label and indication. Whether it’s appropriate for a given person depends on medical history, other conditions, cost and insurance coverage, and tolerance for GI side effects, all of which is a conversation for a clinician, not a headline statistic.